Literature DB >> 3126408

Erratic gastric emptying of levodopa may cause "random" fluctuations of parkinsonian mobility.

R Kurlan1, K P Rothfield, W R Woodward, J G Nutt, C Miller, D Lichter, I Shoulson.   

Abstract

The pathogenesis of "random" fluctuations in parkinsonian mobility, which are not clearly related to the dosing schedule of levodopa, has not been determined. We rated parkinsonian mobility and assayed plasma dopa in one patient with clinically random fluctuations during two modes of administration of levodopa/carbidopa: (1) standard oral route and (2) direct duodenal delivery via nasoduodenal tube. During oral therapy, mobility varied unpredictably in relation to levodopa dosing, suggesting a clinically random pattern. During duodenal delivery, however, a predictable and dramatic pattern of recurrent end-of-dose deterioration was observed; each intraduodenal levodopa dose resulted in 60 to 90 minutes of benefit. Plasma dopa levels correlated closely with mobility ratings for both modes of administration. Our findings indicate that erratic gastric emptying of levodopa is responsible for apparently "random" oscillations in mobility in at least one patient with Parkinson's disease and probably in others.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3126408     DOI: 10.1212/wnl.38.3.419

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  41 in total

1.  The clinical use of apomorphine in Parkinson's disease.

Authors:  M J Steiger; N P Quinn; C D Marsden
Journal:  J Neurol       Date:  1992-08       Impact factor: 4.849

Review 2.  Gastrointestinal features of Parkinson's disease.

Authors:  Leslie J Cloud; James G Greene
Journal:  Curr Neurol Neurosci Rep       Date:  2011-08       Impact factor: 5.081

3.  Gastric emptying in healthy volunteers after multiple doses of levodopa.

Authors:  D G Waller; C Roseveare; A G Renwick; B Macklin; C F George
Journal:  Br J Clin Pharmacol       Date:  1991-12       Impact factor: 4.335

4.  Clinical and pharmacokinetic comparison of oral and duodenal delivery of levodopa/carbidopa in patients with Parkinson's disease with a fluctuating response to levodopa.

Authors:  D Deleu; G Ebinger; Y Michotte
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

5.  The influence of levodopa on gastric emptying in man.

Authors:  D R Robertson; A G Renwick; N D Wood; N Cross; B S Macklin; J S Fleming; D G Waller; C F George
Journal:  Br J Clin Pharmacol       Date:  1990-01       Impact factor: 4.335

6.  The influence of net water absorption on the permeability of antipyrine and levodopa in the human jejunum.

Authors:  D Nilsson; U Fagerholm; H Lennernäs
Journal:  Pharm Res       Date:  1994-11       Impact factor: 4.200

7.  Clinical and pharmacokinetics equivalence of multiple doses of levodopa benserazide generic formulation vs the originator (Madopar).

Authors:  Margherita Torti; Jhessica Alessandroni; Daniele Bravi; Miriam Casali; Paola Grassini; Chiara Fossati; Cristiano Ialongo; Marco Onofrj; Fabiana Giada Radicati; Laura Vacca; Stefano Bonassi; Fabrizio Stocchi
Journal:  Br J Clin Pharmacol       Date:  2019-09-12       Impact factor: 4.335

8.  Pharmacokinetics of levodopa, carbidopa, and 3-O-methyldopa following 16-hour jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson's disease patients.

Authors:  Dag Nyholm; Per Odin; Anders Johansson; Krai Chatamra; Charles Locke; Sandeep Dutta; Ahmed A Othman
Journal:  AAPS J       Date:  2012-12-11       Impact factor: 4.009

Review 9.  Oral and infusion levodopa-based strategies for managing motor complications in patients with Parkinson's disease.

Authors:  Angelo Antonini; K Ray Chaudhuri; Pablo Martinez-Martin; Per Odin
Journal:  CNS Drugs       Date:  2010-02       Impact factor: 5.749

Review 10.  Potential of transdermal drug delivery in Parkinson's disease.

Authors:  Ronald F Pfeiffer
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.